Collecting Duct Carcinoma — Clinical Trials

MONDO:00052206 active·3 recruitingLast updated: Mar 15, 2026, 6:06 PM

Trial Landscape

Collecting Duct Carcinoma has a growing clinical research program, driven by drug treatment and procedure.

Recruiting

Active Trials

By Approach

Drug Treatment6

Procedure2

Biological Therapy1

1 additional trials involve behavioral, dietary, diagnostic, or observational approaches.

By Phase

Phase 2

Sponsor Types

Academic/Other4NIH2

Trial Locations

United States4 trials

China1 trial

Italy1 trial

Puerto Rico1 trial

Trials often recruit across multiple countries, so totals exceed the trial count.

6 Trials

Phase 2Recruiting

NCT03866382

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Sponsor:National Cancer Institute (NCI)

United StatesStarted: May 2019Est. completion: Feb 2027Updated: Mar 2026

Phase 2Recruiting

NCT06302569

Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma

Sponsor:Giuseppe Procopio

ItalyStarted: May 2025Est. completion: May 2029Updated: Sep 2025

Phase 2Recruiting

NCT06211114

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

Sponsor:Peking University Cancer Hospital & Institute

ChinaStarted: Feb 2024Est. completion: Feb 2027Updated: Nov 2024

Phase 2Active, Not Recruiting

NCT04071223

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Sponsor:National Cancer Institute (NCI)

United StatesStarted: Jul 2020Est. completion: Oct 2026Updated: Mar 2026

Phase 2Active, Not Recruiting

NCT04413123

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

Sponsor:Bradley A. McGregor, MD

United StatesStarted: Nov 2020Est. completion: Dec 2026Updated: Jan 2026

Phase 2Active, Not Recruiting

NCT03635892

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

Sponsor:Memorial Sloan Kettering Cancer Center

United StatesStarted: Aug 2018Est. completion: Aug 2026Updated: Sep 2025

Stay informed about clinical trials for Collecting Duct Carcinoma.

Follow this disease to get updates when trials open, close, or change status.

Follow This Disease — Free

Already have an account? Sign in to manage your watchlists.

Data sourced from ClinicalTrials.gov via Kisho's automated pipeline. Trials refreshed every 4 hours for monitored diseases.

Last sync: March 15, 2026 at 6:06 PM

Collecting Duct Carcinoma — Clinical Trials

Trial Landscape

By Approach

By Phase

Sponsor Types

Trial Locations

6 Trials

Open Trials3

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

Active Trials3

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma